Sterling generic naloxone
Executive Summary
Sterling ANDA for 0.02 mg/ml naloxone HCI given prospective approval by FDA April 18. Final approval is delayed by exclusivity until Sept. 24, 1986. Sterling licenses naloxone from DuPont for use in Talwin Nx (pentazocine/naloxone). Sterling will market the drug as part of its Carpuject product line to hospitals, which primarily consists of analgesics.